How many investments has Proto Axiom made?

Proto Axiom has 9 tracked investments, including 1 dated in the last 24 months.

What stage does Proto Axiom invest at?

Proto Axiom invests at the Pre-Seed, Seed stages.

What sectors does Proto Axiom focus on?

Proto Axiom focuses on Biotech, Deep Tech, FemTech, Healthtech, Medical Devices.

Where is Proto Axiom located?

Proto Axiom is headquartered in Sydney, AU.

Does Proto Axiom lead rounds?

Yes, Proto Axiom leads investment rounds.

Proto Axiom

Venture studio

Sydney · Pre-Seed–Seed · 28 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Proto Axiom operates as a venture studio, building the companies it invests in rather than solely backing external founders. Based in Sydney and established in 2021, the firm centers its work on Australian science combined with what it describes as pharma-grade execution. Its associated initiatives, including a Challenger Summit and a Women's Health Foundry, suggest a focus on science-driven, health-related company creation.

Invests inBiotech Deep Tech FemTech Healthtech Medical Devices Asia-Pacific Australia Sydney

Source: firm website, verified Aug 3, 2026.

Stage

Pre-Seed–Seed

Sydney, AU

Leads rounds

Leads

Instruments

Equity

Founded

2021

Last 12 months

1 investment

Tracked investments

Team · 28 people

from the firm's website

Anthony Liveris· Chief Executive Officer· Sydney, New South Wales, Australiain

Founding CEO of Proto Axiom, building it into a company-creation platform focused on Australian science. Previously co-founded Applecart, a New York data and technology company that received a US$100M investment from Blackstone Growth.

Tony Haddad· Operating Partner

Operating Partner focused on operations.

Anand Gautum· Chair, Strategic Advisors

Chair of Strategic Advisors with experience at Pfizer and Novo Nordisk.

Annalisa Jenkins· Non-Executive Director

Non-Executive Director, former CEO of Dimension Therapeutics and former Head of Global Drug Development at Merck Serono, contributing to development of over 30 therapeutics.

Brian Ledwith· Chair, Scientific Advisory Board

Chair of the Scientific Advisory Board with over 30 years in vaccines and gene therapy.

Charlie Selth· Chief of Staff· Sydney, New South Wales, Australiain

Chief of Staff focused on strategy.

Gavin MacLaren· Chair· Australiain

Board chairman with over 20 years as a lawyer, including a decade in Asia. Named an Innovative Leader in the 2020 FT Innovative Lawyers Awards Asia Pacific.

Hugh McGonagle· Chief Operating Officer· Greater Sydney Areain

Chief Operating Officer with a legal and risk background.

Iain Mackay· Strategic Advisor

Strategic Advisor and former CFO of GSK and HSBC.

James Rush· Scientific Advisor

Scientific Advisor with experience at Novartis and Spica Therapeutics.

John Roach· Head of Finance· Greater Sydney Areain

Head of Finance with finance and pharma operations experience.

Kathy Connell· Non-Executive Director

Non-Executive Director with two decades in life-sciences business development and investment at Johnson & Johnson and Sanofi, deploying over US$1B across ANZ in licensing and acquisitions.

Laura Wimberger· Investment Associate· Greater Sydney Areain

Investment Associate with a PhD.

Lawrence Gozlan· Strategic Advisor

Strategic Advisor and CIO of Scientia Capital.

Lindsay Wu· Chief Science Officer· Greater Sydney Areain

Chief Science Officer focused on drug development and translation.

Marina Naidion· Business Manager

Business Manager.

Michael Sierra· Scientific Advisor

Scientific Advisor with experience at LEO Pharma and GlaxoSmithKline.

Michelle Burke· Strategic Advisor

Strategic Advisor associated with AusBiotech and PBAC.

Nicholas Hunt· Entrepreneur in Residence· Sydney, New South Wales, Australiain

Entrepreneur in Residence with a founder-operator background in nanomedicine.

Peter Devine· Non-Executive Director

Non-Executive Director who spent 20 years as CEO of Uniseed, the A$200M partnership between Australian research institutions and UniSuper, and led multiple biotech exits.

Richard Wang· Science Analyst

Science Analyst with a PhD.

Rob McInnes· Strategic Advisor

Strategic Advisor specializing in IP advisory, associated with Spruson & Ferguson.

Russell Basser· Scientific Advisor

Scientific Advisor with experience at CSL Ltd and Starpharma.

Sally Bennett· Non-Executive Director

Non-Executive Director and Senior Advisor at Catalio Capital Management, with over 25 years across medicine, equity capital markets and life-sciences investment management.

Sara Althari· Scientific Advisor

Scientific Advisor associated with the Saudi Ministry of Investment.

Tom Harley· Non-Executive Director

Non-Executive Director and Managing Director of Dragoman. Former President of Corporate Development at BHP and former Non-Executive Chairman of Dow Chemical Australia.

Tristan Edwards· Non-Executive Director

Non-Executive Director, co-founder and first CEO of Boston-based Life Biosciences, with 18 years in global funds management at Goldman Sachs Asset Management and Brevan Howard.

William Marshall· Scientific Advisor

Scientific Advisor affiliated with UMass Medical and Harvard Medical.

Founder mafia

2 people who came through Proto Axiom went on to found or lead other companies.

Anthony LiverisChief Executive OfficerFounded Applecart Lindsay WuChief Science OfficerFounded JumpStart Fertility

What they invest in

from 4 of 9 portfolio companies

Biotech ×3Deep Tech ×2Healthtech ×2Medical Devices ×1New Materials ×1

HQs:United States×2Australia×1

Investments · 9 tracked

founders shown can be your intro path

By year:2026 · 1 2017 · 12 dated

AdvanCelladvancell.com.au inJun 2026

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

Andrew Adamovich(Director)Philina Lee(Executive Officer, Director)Aaron Pickett(Executive Officer)

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsBain Capital Life Sciences Catalio Capital Management, LP SV Health Investors Tenmile Abingworth Ally Bridge Group +1 more

Amazing Gut

Cellutech

Endo Axiom

ProtoAxiom is an investment and company-building firm focused on Australian life science companies.

BiotechDeep TechSydney, AU

Flo Axiomfloaxiom.com

Floaxiom develops NanoSurface, a biologically manufactured affinity nanoparticle platform for antibody (mAb) purification, offering a chromatography-free alternative to protein A resin columns and membrane systems.

BiotechDeep TechNew Materials

Herikin

JumpStart FertilityJul 2017

HealthtechChestnut Hill, US

Lindsay E. Wu(Executive Officer, Director)inDavid Sinclair(Director)Michael Sistenich(Director)Hayden Homer(Director)Alexander Tristan Edwards(Director)

Co-investorsLife Biosciences

Onyx Axiom

Therapeutics company formed from Australian translational science, with a topical antifungal lead in Phase IIb; supported by Proto Axiom's operating bench.

SWAN Genomics

Platform opportunity sourced from UNSW; Proto Axiom co-creator focused on platform commercialisation strategy and team building.

Portfolio news

latest coverage across their companies

AdvanCell has filed a notice of an exempt offering of securities to raise $315 Million in New Funding. - intelligence360

AdvanCell · intelligence360.news · Aug 4, 2026

Frequently asked questions

How many investments has Proto Axiom made?: Proto Axiom has 9 tracked investments, including 1 dated in the last 24 months.
What stage does Proto Axiom invest at?: Proto Axiom invests at the Pre-Seed, Seed stages.
What sectors does Proto Axiom focus on?: Proto Axiom focuses on Biotech, Deep Tech, FemTech, Healthtech, Medical Devices.
Where is Proto Axiom located?: Proto Axiom is headquartered in Sydney, AU.
Does Proto Axiom lead rounds?: Yes, Proto Axiom leads investment rounds.
Who does Proto Axiom co-invest with?: Proto Axiom most often shares deals with Bain Capital Life Sciences, Catalio Capital Management, LP, SV Health Investors, among 4 tracked co-investors.

Similar investors

Future Positive Capital

Future Positive Capital is a European deep-tech fund that ties its entire thesis to the Future Cones foresight framework, explicitly focusing on preferable futures and positioning itself as a futures-thinking, systems-change VC rather than a generic climate or impact fund. The firm hard-wires impact into its economics by contractually indexing more than 100% of partners' carried interest to portfolio companies achieving both financial and measurable impact outcomes, while specializing in capital-intensive, highly technical step-change solutions for planetary-scale problems like robotics for wind farm operations, large-scale carbon removal, and ecosystem restoration.

Sv Tech Ventures, Inc.

SV Tech Ventures is a Palo Alto-based venture capital firm investing in early-stage, high-tech startups, offering hands-on support with strategy, product, fundraising, and hiring across its funds.

Overwater Ventures Llc

Overwater Ventures is an early-stage venture firm that partners with pre-seed and seed stage founders working on large-scale problems, offering hands-on support across launch strategy, go-to-market, fundraising, and marketing.

$400K – $2M

Industrifonden

Industrifonden is a venture capital fund that backs transformative, scalable innovations aimed at improving society, partnering with founders across life science, deeptech, and industrial technology sectors.